Rafael Holdings, Inc.

Equities

RFL

US75062E1064

Real Estate Development & Operations

Market Closed - Nyse Other stock markets 04:10:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.72 ^USD	+0.88%		-1.15%	-6.01%

Mar. 13	Rafael Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI
2023	North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment	DJ

Rafael Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended July 31, 2023

October 30, 2023 at 04:14 pm EDT

Rafael Holdings, Inc. reported earnings results for the fourth quarter ended July 31, 2023. For the fourth quarter, the company reported sales was USD 0.068 million compared to USD 0.069 million a year ago. Net income was USD 1.16 million compared to net loss of USD 4.78 million a year ago.

Basic earnings per share from continuing operations was USD 0.06 compared to basic loss per share from continuing operations of USD 0.24 a year ago. Basic earnings per share was USD 0.06 compared to basic loss per share of USD 0.24 a year ago.

Latest news about Rafael Holdings, Inc.

Rafael Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	Mar. 13	CI
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment	Dec. 19	DJ
Tranche Update on Rafael Holdings, Inc.'s Equity Buyback Plan announced on April 4, 2023.	Dec. 14	CI
Rafael Holdings, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	Dec. 14	CI
North American Morning Briefing : Traders Eye -2-	Dec. 12	DJ
Tranche Update on Rafael Holdings, Inc.'s Equity Buyback Plan announced on April 4, 2023.	23-10-30	CI
Rafael Holdings, Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	23-10-30	CI
Rafael Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended July 31, 2023	23-10-30	CI
Earnings Flash (RFL) RAFAEL HOLDINGS Reports Q4 Revenue $68,000	23-10-30	MT
Earnings Flash (RFL) RAFAEL HOLDINGS Reports Q4 EPS $0.06	23-10-30	MT
Rafael Holdings, Inc. Announces Resignation of Rachel Jonas as Director	23-10-26	CI
Rafael Holdings, Inc. Announces Resignation of Boris Pasche as Director	23-08-09	CI
Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.	23-08-01	CI
Rafael Holdings, Inc.'s Equity Buyback Plan Extended till July 1, 2024.	23-06-30	CI
Rafael Holdings, Inc.'s Equity Buyback announced on April 4, 2023, has expired.	23-06-15	CI
Tranche Update on Rafael Holdings, Inc.'s Equity Buyback Plan announced on April 4, 2023.	23-06-13	CI
Rafael Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-13	CI
Cyclo Therapeutics Signs $5 Million Funding Deal with Rafael Holdings	23-06-05	MT
Cyclo Therapeutics, Inc. announced that it expects to receive $5 million in funding from Rafael Holdings, Inc.	23-05-31	CI
Cyclo Therapeutics, Inc. announced that it has received $2.1 million in funding from Rafael Holdings, Inc.	23-05-01	CI
Rafael Holdings, Inc. announces an Equity Buyback for $5 million worth of its shares.	23-04-04	CI
Rafael Holdings, Inc. authorizes a Buyback Plan.	23-04-03	CI
Rafael Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-14	CI
Rafael Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-14	CI
Protara Therapeutics Names Patrick Fabbio Financial Chief	23-01-30	MT

Chart Rafael Holdings, Inc.

Duration

Period

More charts

Company Profile

Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. The Company's segments include healthcare and real estate. The Company's investments include Cornerstone Pharmaceuticals, Inc., which is a cancer metabolism-based therapeutics company; LipoMedix Pharmaceuticals Ltd., which is a clinical-stage pharmaceutical company; Barer Institute Inc., which is a preclinical cancer metabolism research operation; Cyclo Therapeutics Inc., which is a clinical-stage biotechnology company dedicated to developing medicines for patients and families living with diseases through its therapeutic asset like Trappsol and Cyclo; Day Three Labs, Inc., which offers pharmaceutical-grade technology like Unlokt, and Rafael Medical Devices, LLC, which is an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries. Its real estate segment comprises of a portion of a commercial building in Israel.

Sector

Real Estate Development & Operations

Calendar

2024-06-10 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Real Estate Development & Operations

	1st Jan change	Capi.
RAFAEL HOLDINGS, INC.	-6.01%	42.29M
MITSUI FUDOSAN CO., LTD.	+39.94%	28.07B
SUN HUNG KAI PROPERTIES LIMITED	-13.85%	26.92B
DLF LIMITED	+22.78%	26.28B
CHINA RESOURCES LAND LIMITED	+1.61%	26.06B
MITSUBISHI ESTATE CO., LTD.	+49.67%	22.69B
EMAAR PROPERTIES	+3.79%	19.59B
CHINA OVERSEAS LAND & INVESTMENT LTD.	+5.96%	20.3B
SUMITOMO REALTY & DEVELOPMENT CO., LTD.	+30.95%	16.31B
CK ASSET HOLDINGS LIMITED	-14.16%	15.03B

Other Real Estate Development & Operations